kras(g12c)

MRTX-1257 is a selective, irreversible, and covalent inhibitor of KRAS G12C with an IC50 of 900 pM for KRAS-dependent ERK phosphorylation in H358 cells. MRTX-1257 demonstrated 31% bioavailability in the mouse, with free fraction exposures well above cellular potency, and 77% target engagement in a PK/PD experiment.

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

KRAS G12C Inhibitor 13 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12C inhibitor 14 is a potent compound with an IC50 of 18 nM [1].

KRAS G12C inhibitor 15 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

KRas G12C inhibitor 2 is a compound specifically designed to inhibit the KRas G12C mutation.

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 5 is a KRas G12C inhibitor. (Add a sentence that describes its primary function, mechanism, or application.)

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.

KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.

KRAS G12C inhibitor 63 (K45) is a KRAS G12C inhibitor that can induce apoptosis and exhibits antitumor activity.

KRAS G12C Ligand-Linker Conjugates 1 are compounds formed by the conjugation of a KRASG12C ligand and a linker, utilized in the synthesis of PROTAC YF135.

KRAS G12C degrader-2 is an E3 ligase ligand-linker conjugate, incorporating a CRBN-based ligand and a linker, suitable for synthesizing PROTAC.

LC-2 (PROTAC KRASG12C Degrader-LC-2) is a novel von Hippel-Lindau-based PROTAC degrader of endogenous KRAS G12C with a DC50 between 0.25 and 0.76 μM.LC-2 is a PROTAC that covalently binds KRAS G12C with MRTX849 and recruits the E3 ligase, VH, to induce a rapid and sustained degradation of KRAS G12C. LC-2 inhibits MAPK signaling in pure and heterozygous KRAS G12C cell lines.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.

KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.

KRAS G12C inhibitor 33 is a KRAS G12C inhibitor used in cancer research.